- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01679756
INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer (INEXTREMO)
INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer: a Randomized Clinical Trial. (IN EXTREMO Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background. Only a few retrospective publications comparing these anastomotic techniques and no randomized clinical trial has been performed. We conducted a meta-analysis of the existing non randomized comparative studies on the argument: the results suggest that the IA results in better postoperative recovery outcomes, such as shorter hospital stay, faster bowel movement recovery, faster first flatus, faster time to solid diet and lesser analgesic usage.
Design: Two-armed, double-blinded, randomized, controlled study.
The patients will be randomized into two groups:
A. After laparoscopic right colectomy for cancer, anastomosis will be carried out intracorporeally (IA) B. After laparoscopic right colectomy for cancer, anastomosis will be carried out extracorporeally (EA)
Primary endpoint: Surgical morbidity rate defined as any diagnosed morbidity related to surgical technique (anastomotic leakage, anastomotic bleeding, wound infection, ileus) within 60 days from surgery.
Secondary endpoints:
- Intra-operative: operative time, largest incision length (mm), number of nodes harvested, intraoperative complications.
- Early postoperative: mortality, non-surgical site complications.
- Postoperative recovery: bowel movement, first flatus, time to solid diet, nasogastric tube (NGT) reintroduction, day of analgesic usage, length of stay, readmission.
Randomization. The randomization will be obtained through a computer generated program (GraphPad Software, Inc, La Jolla, California, USA). The randomization, will be done before the beginning of the study and it will consist with an ordered series of numbers with a corresponding letter: A for intracorporeal anastomosis and B for extracorporeal anastomosis. This series of numbers will be kept in a central dedicated web database; after right colon cancer diagnosis, if the patient fulfills the inclusion criteria and signs the consent a number, progressive as in order of inclusion, will be assigned to him or her. The letter corresponding to the number, and hence the type of procedure to perform, will be notified to the operating surgeon, who will proceed accordingly.
Blinding. A second surgeon team (different from the one who participate in the intervention), aware of the operative findings but not the management of the anastomosis, will then assume the care of the patient. Postoperative care and ability to be discharged from the hospital will be determined by the second surgical team. This second surgical team will be blinded to the kind of anastomosis. The primary operative team will be in every moment available for emergent consultation.
Power Calculation. The reported prevalence of surgical morbidity after laparoscopic colectomy varies widely from 5-15%16-39, usually depending on the definition of complications and the type of resection performed. The most recent Cochrane review on the argument indicates a 8.6% of local morbidity (Wound infection, anastomotic insufficiency, postoperative ileus, postoperative bleeding)40. Therefore the number of patients required was based on the hope of improving the rate of surgical morbidity from 8.6% to 4.3%; considering a drop-out rate of 5%, 384 patients (192 in the IA group and 192 in the EA group) are necessary to ensure an 80% power with an alpha of 5%, when using a two-sided log-rank test. The statistical power sample calculation was carried out using PASS 2005 (Power Analysis and Sample Size, within the statistical package "NCSS 2004 and PASS 2005").
Sixty-four patients will be included by each of the six centers of the consortium. Only surgeons with at least 30 right colectomies performed with intracorporeal anastomosis will be allowed to recruit patients as first operator.
Statistics. To evaluate significance of differences between the two groups, chi-squared and Fisher's exact test will be used as appropriated for categorical variables, and the non-parametric Mann-Whitney U-test for continuous variables. Significance level will be set at 5%. The statistical analysis will be carried out using the Statistical Package for the Social Sciences (SPSS version 13; SPSS Inc. Chicago, Illinois, USA).
Monitoring. as commonly requested for Randomized Controlled Trials on patients, a strict control of outcomes has been planned during the study. Three experts in laparoscopic colorectal surgery will be designed as member of IN EXTREMO Trial Monitoring Committee. They would have access to the data during the whole course of the study and indicate cessation of the trial if one arm is providing manifestly inferior results.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Francesco Feroci, MD
- Phone Number: +393398382381
Study Locations
-
-
Po
-
Prato, Po, Italy, 59100
- Misericordia e Dolce Hospital
-
Sub-Investigator:
- Maddalena Baraghini, MD
-
Contact:
- Francesco Feroci, MD
- Phone Number: +393398382381
- Email: fferoci@yahoo.it
-
Sub-Investigator:
- Andrea Vannucchi, MD
-
Principal Investigator:
- Elisa Lenzi, MD
-
Sub-Investigator:
- Alessia Garzi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Patients suitable for curative surgery 18-80 years old
- ASA grade I-III
- Histhopatological confirmed right only colon carcinoma.
- Elective interventions
- Laparoscopic surgery
- Informed consent
Exclusion criteria
- Informed consent refusal
- Metastatic disease
- Not right colon cancer
- Non elective procedure
- Open or converted operations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intracorporeal anastomosis
Laparoscopic right hemicolectomy for cancer.
.For the IA group, colon, transverse mesocolon, ileum and terminal ileum mesentery will be resected intracorporeally through a 45 mm endoscopic linear stapler with vascular cartridge.
Then, the linear stapler will inserted through two small enterotomies and a mechanical ileo-transverse, side-to-side isoperistaltic intracorporeal anastomosis performed using the vascular cartridge with six rows of closely placed staples.
The enterotomies will be then closed using a double layered continuous intra corporeal manual suture with 3-0 Polyglactin 910.
The mesenteric defects will be left open.
The specimen will be placed in a protective plastic bag and then extracted through a Pfannestiel incision.
|
After induction of anesthesia, a foley catheter and an NG tube will be inserted.
All patients will have their NG tubes removed after the procedure.
During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees).
A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure.
Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall.
The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips.
Anastomosis are described in each arm description.
|
Active Comparator: Extracorporeal anastomosis
Laparoscopic right hemicolectomy for cancer. In the EA group, the bowel will be externalized by widening the incision of one of the trocars or by performing a mini-laparotomy at another location (subcostal, suprapubic) protected with a plastic sheet. The ileum and colon will be then resected through a 45 mm endoscopic linear stapler with vascular cartridge (staple height = 3.85 mm) and a side-to-side isoperistaltic mechanical anastomosis will be then performed using the same vascular cartridge. The enterotomies will be then closed using a double layered continuous manual suture using a 3-0 Polyglactin 910. In both groups, a drain will not routinely inserted. |
After induction of anesthesia, a foley catheter and an NG tube will be inserted.
All patients will have their NG tubes removed after the procedure.
During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees).
A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure.
Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall.
The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips.
Anastomosis are described in each arm description.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall surgical morbidity
Time Frame: 60 days from surgery
|
Surgical morbidity rate defined as any diagnosed morbidity related to surgical technique (anastomotic leakage, anastomotic bleeding, wound infection, ileus) within 60 days from surgery.
|
60 days from surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operative time
Time Frame: day of intervention
|
Minutes from skin incision to skin closure
|
day of intervention
|
Largest incision length
Time Frame: day of intervention
|
millimeters of skin incision
|
day of intervention
|
Numbers of node harvested
Time Frame: day of intervention
|
Numbers of node harvested
|
day of intervention
|
Intraoperative complicatons
Time Frame: day of intervention
|
Incidence and kind of intraoperative morbidity
|
day of intervention
|
Mortality
Time Frame: 60 days from surgery
|
Incidence and kind of intraoperative morbidity
|
60 days from surgery
|
Non surgical site complications
Time Frame: 60 days from surgery
|
Incidence and kind of medical morbidity (cardiovascular, respiratory, or metabolic events; nonsurgical infections; deep venous thrombosis; and pulmonary embolism)
|
60 days from surgery
|
Bowel movement
Time Frame: 10 days from surgery
|
Defined as hours from surgery to peristalsis, assessement every 8 hours
|
10 days from surgery
|
First flatus
Time Frame: 10 days from surgery
|
Defined as hours from surgery to first flatus
|
10 days from surgery
|
First stool canalization
Time Frame: 10 days from surgery
|
Defined as hours from surgery to first stool canalization
|
10 days from surgery
|
Time to solid diet
Time Frame: 10 days from surgery
|
Defined as hours from surgery to solid diet tolerance
|
10 days from surgery
|
Naso gastric tube reintroduction
Time Frame: 60 days from surgery
|
Defined as rate of NGT reintroduction
|
60 days from surgery
|
Days of analgesic usage
Time Frame: 60 days from surgery
|
Defined as number of days after interventions
|
60 days from surgery
|
Length of hospital stay
Time Frame: 60 days from surgery
|
Defined as day from surgery to dismission plus eventual days of recovery after readmission
|
60 days from surgery
|
Readmission
Time Frame: 60 day from intervention
|
Rate of readmission after home dimission
|
60 day from intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Marco Scatizzi, MD, Misericordia e Dolce Hospital
- Study Director: Francesco Feroci, MD, Misericordia e Dolce Hospital
- Principal Investigator: Stefano Cantafio, MD, Misericordia e Dolce Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EAES 7625
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Laparoscopic right hemicolectomy for cancer
-
Pamela Youde Nethersole Eastern HospitalCompletedRecurrence | Pain Score | Survival | Operation TimeHong Kong
-
Jeremy MeyerUniversity Hospital, Geneva; Hôpital Fribourgeois; Spital Biel, SwitzerlandNot yet recruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Adenocarcinoma | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Neoplasms, Benign
-
Zhejiang UniversityRecruitingHepatic Flexure Colon Cancer | Proximal Transverse Colon CancerChina
-
Corporacion Parc TauliAnna Pallisera-Lloveras; Sheila Serra-Pla; Mireia Pascua-Solé; Laura Mora-Lopez; Ricard... and other collaboratorsCompleted
-
Amsterdam UMC, location VUmcProf. dr. P.J. Tanis, colorectal surgeon; Dr. B.R. Toorenvliet, colorectal... and other collaboratorsNot yet recruitingTraining | Implementation | Assessment | Consolidation | Colonic Carcinoma | Laparoscopic Right Hemicolectomy | Standardisation | Delphi StudyNetherlands
-
University of Roma La SapienzaCompletedColorectal Laparoscopic ResectionItaly
-
Xu jianminCompleted
-
Yonsei UniversityEnrolling by invitationAdenocarcinoma of the ColonKorea, Republic of
-
University of British ColumbiaTyco Healthcare GroupWithdrawnColon Cancer
-
Zhejiang UniversityCompletedHepatic Flexure Colon Cancer | Proximal Transverse Colon CancerChina